Monographie - Daptomycin

Utolsó frissítés :
19/11/2024

Daptomycin

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Cubicin	Amerikai Egyesült Államok, Argentína, Ausztria, Chile, Colombia, Dánia, Finnország, Franciaország, Görögország, Hollandia, India, Írország, Izland, Japán, Kanada, Lengyelország, Luxemburg, Magyarország, Malaysia, Mexikó, Nagy-Britannia, Németország, Norvégia, Olaszország, Portugália, Románia, Spanyolország, Svájc, Svédország, Törökország, új-Zéland, Venezuela
Daptomicina	Spanyolország
Daptomicine	Nagy-Britannia

Irodalom : Daptomycin

	Type	publikáció
1937	Napló	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
2247	Napló	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Napló	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2271	Laboratórium	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
3122	Napló	Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3218	Napló	Peyro Saint Paul L, Albessard F, Gaillard C, Debruyn D, Ryckelynck J Ph, Antoine Coquerel, Lobbedez T Daptomycin Compatibility in Peritoneal Dialysis Solutions Perit Dial Int 2011 ; 31: 492?495.
3439	Napló	Parra M.A, Campanero M.A, S?daba B, Irigoyen A, Garc?a-L?pez L,Fernandez-Reyes M.J, Ramon Azanza J. Effect of Glucose Concentration on the Stability of Daptomycin in Peritoneal Solutions. Perit Dial Int 2013 ; 33:458-461
3665	Napló	Ortega R, Salmer?n-Garc?a A, Cabeza J, Capit?n-Vallvey L.F, Navas N. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C. Am J Health-Syst Pharm 2014 ; 71:956-959
3827	poszter	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poszter	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poszter	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3976	Napló	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Napló	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4074	Napló	Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. Stability of daptomycin reconstituted vials and infusion solutions. EJHP 2018 ; 25: 107-110.
4145	Napló	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254	Napló	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4380	Laboratórium	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4528	Napló	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Napló	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales